Galapagos' CAR-T therapy GLPG5101 shows promise but faces challenges with limited data, cash reserves, and competition in the ...

Gilead subsidiary Kite has been a pioneer in the autologous CAR T-cell therapy space. The drugmaker markets Yescarta ...

This early data has demonstrated a clear improvement in GLPG5101 efficacy over its competitors in iNHL and MCL.

These long-term data support axicabtagene ciloleucel as a highly effective therapeutic approach for patients with relapsed or ...

Gilead Sciences presents five-year Phase II ZUMA-5 trial results for Yescarta in relapsed non-Hodgkin lymphomas, showing a 90 ...

Gilead’s (NASDAQ:GILD) Kite unit reported positive results from a five-year follow-up of a Phase 2 study for its cell therapy Yescarta in certain patients with non-Hodgkin lymphoma, or NHL. The ...

Smith, a leading global distributor of electronic components and semiconductors, today announces it has been named Featured International Branded Distributor under the Featured Electronic Components ...

Kite, a Gilead Company, announced results from a five-year follow-up analysis of ZUMA-5, a Phase 2 study of Yescarta in patients with relapsed/refractory no ...

Lymphoma patients better tolerated the CAR T-cell therapy manufactured on site at the Sheba Medical Center than they did the ...

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), AbbVie Inc.

GlobalData’s analysts predict $158 million in global sales for AZD0486 by 2030, with $2.4 billion for Epkinly and $949 million for Lunsumio.

Kite, a Gilead Company (Nasdaq: GILD), today announced findings from three new analyses for Yescarta® (axicabtagene ciloleucel) that demonstrate improved outcomes for people living with relapsed or ...